• Pathologic (histology or cytology) confirmed diagnosis of epithelial ovarian cancer or endometrial cancer

• Radiographic evidence of recurrent epithelial ovarian cancer (ovarian, fallopian tube, or primary peritoneal cancer) or endometrial cancer that is platinum-sensitive, defined as progression of disease beyond 6 months from the last dose of platinum-based chemotherapy

• Female, age ≥ 18 years

• World Health Organization (WHO) performance status 0-1 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks

• Patient has measurable disease (at least one lesion that can be accurately assessed repeatedly by CT) as evidenced on pre-treatment baseline CT of Chest/Abdomen/Pelvis or PET/CT, or evaluable disease

• Adequate hematologic counts, as defined below, without transfusion or growth factor support within 2 weeks of study drug initiation:

‣ Hemoglobin ≥ 8.5 g/dL

⁃ Absolute neutrophil count ≥ 1500/mm3

⁃ Platelets ≥ 100,000/μL

• Adequate organ function as defined below:

‣ Total bilirubin ≤ 1.5 ULN

⁃ AST(SGOT)/ALT(SPGT) ≤ 2.5x ULN or ≤ 5 x ULN if known liver metastases

⁃ Serum albumin \> 3 g/dL

⁃ Creatinine clearance ≥ 50 mL/min per the Cockcroft-Gault equation

• Women of childbearing potential must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 6 months following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

• o A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

⁃ Has not undergone a hysterectomy or bilateral oophorectomy; or

⁃ Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).

• Ability to understand and the willingness to sign a written informed consent.